Oncogenic activating mutations in epigenetic modifiers (i.e., IDH1/2, EZH2, and DNMT3A) and inactivating mutations in chromatin modifiers (i.e., KDM6A, CREBBP, EP300, and SMARCB1) have been observed in ALL [24,93]. This evidence concerns the gene CREBBP and acute lymphoblastic leukemia.